Under the agreement, Lundbeck and Proximagen will jointly apply their expertise in CNS drug development.
As part of the agreement, a steering committee involving experts from both companies will focus on developing three of Proximagen’s programmes, with the aim of identifying innovative therapies to treat serious diseases including epilepsy, pain and inflammatory disorders.
Lundbeck Research and Development executive vice president Anders Gersel Pedersen said this strategic partnership will provide Lundbeck with exposure to some very exciting research programmes.